BIOMAT Database Logo BIOMAT Database Logo

Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. 2004

Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland 21250, USA.

Mouse tumor cells transfected with syngeneic MHC class II and costimulatory molecule genes are therapeutic vaccines in mice, provided they do not coexpress the class II-associated invariant chain (Ii). We demonstrated previously that the vaccine cells present tumor peptides via the endogenous antigen presentation pathway to activate CD4(+) and CD8(+) T cells. Because of their efficacy in mice, we are translating this vaccine strategy for clinical use. To obtain MHC class II(+)CD80(+)Ii(-) human tumor cells, we developed retroviruses encoding HLA-DR and CD80. The HLA-DR virus encodes the DRalpha and DRbeta0101 chains using an internal ribosomal entry site to coordinate expression. SUM159PT mammary carcinoma and Mel 202 ocular melanoma cells transduced with the retroviruses DRB1/CD80 express high levels of DRB0101 and CD80 on the cell surface in the absence of Ii. Irradiated SUM159PT/DR1/CD80 vaccines stimulate proliferation of non-HLA-DRB0101 peripheral blood mononuclear cells and present an exogenous DR1-restricted tetanus toxoid (TT) peptide, indicating that the transduced DRB0101 is functional. SUM159PT/DR1/CD80 vaccines were further transduced with a retrovirus encoding the TT fragment C gene, as a model tumor antigen. These cells stimulate IFN-gamma release from TT-primed human DRB0101 peripheral blood mononuclear cells, demonstrating their ability to present "endogenous" tumor antigen. Depletion and antibody blocking experiments confirm that MHC class II-restricted, endogenously synthesized epitopes are presented to CD4(+) T cells. Therefore, the MHC class II vaccines are efficient antigen-presenting cells that activate tumor-specific MHC class II-restricted, CD4(+) T lymphocytes, and they are a novel and potential immunotherapeutic for metastatic cancers.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D012190 Retroviridae Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES). Leukemogenic Viruses,Leukoviruses,Oncornaviruses,Oncovirinae,Oncoviruses,Oncoviruses, Type C,RNA Tumor Viruses,Retroviruses,Type C Oncoviruses,C Oncovirus, Type,C Oncoviruses, Type,Leukemogenic Virus,Leukovirus,Oncornavirus,Oncovirus,Oncovirus, Type C,RNA Tumor Virus,Retrovirus,Tumor Virus, RNA,Tumor Viruses, RNA,Type C Oncovirus,Virus, Leukemogenic,Virus, RNA Tumor,Viruses, Leukemogenic,Viruses, RNA Tumor
D013745 Tetanus Toxoid Tetanus Vaccine,Toxoid, Tetanus,Vaccine, Tetanus
D014161 Transduction, Genetic The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE. Genetic Transduction,Genetic Transductions,Transductions, Genetic
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte

Related Publications

Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.
November 1996, Proceedings of the National Academy of Sciences of the United States of America,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes.
December 1994, European journal of immunology,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice.
September 1994, European journal of immunology,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Activation of virus-specific major histocompatibility complex class II-restricted CD8+ cytotoxic T cells in CD4-deficient mice.
April 1995, European journal of immunology,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.
May 2007, Journal of virology,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.
October 1994, Journal of leukocyte biology,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
April 1998, Cancer research,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
T-cell receptor usage of major histocompatibility complex class I restricted peptide-specific T-lymphocytes.
July 1995, Annals of the New York Academy of Sciences,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor.
November 1998, The Journal of experimental medicine,
Samudra K Dissanayake, and James A Thompson, and Jacobus J Bosch, and Virginia K Clements, and Peter W Chen, and Bruce R Ksander, and Suzanne Ostrand-Rosenberg
Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.
May 1999, The Journal of experimental medicine,
Copied contents to your clipboard!